share_log

Akanda To Supply Tetra Bio-Pharma With Pharmaceutical-Grade Cannabis For FDA Trials Of QIXLEEF, A Potential Multimillion Dollar Prescription Drug

Benzinga Real-time News ·  Jul 12, 2022 19:35

Provides Tetra with stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and prescription products

Diversifies Akanda into cancer pain medical market as a specialized manufacturer of cannabis-based drugs for use in FDA clinical trials and pharmaceutical markets

LONDON and MONTREAL, July 12, 2022 /PRNewswire/ - Akanda Corp. ("Akanda") (NASDAQ:AKAN) and Tetra Bio-Pharma ("Tetra") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), today jointly announced that Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEFTM and related...

Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment